Stifel lowers Soleno Therapeutics stock price target to $115 on PWS market model refresh

Soleno Therapeutics (SLNO) maintains strong analyst confidence despite Stifel's slight price target reduction to $115 (from $118), which still holds a Buy rating based on a refreshed Prader-Willi Syndrome (PWS) market model projecting a $2+ billion worldwide opportunity for its Vykat treatment. The company benefits significantly from reduced competitive pressure following Acadia Pharmaceuticals' PWS trial failure, prompting H.C. Wainwright, Baird, and TD Cowen to reaffirm positive ratings and targets, alongside the successful launch of Vykat XR.

Analysis

Soleno Therapeutics (SLNO) has experienced a significant de-risking of its commercial outlook for Vykat, its Prader-Willi Syndrome (PWS) treatment, following a pivotal competitive development. The failure of Acadia Pharmaceuticals' (ACAD) Phase 3 trial for a competing PWS drug has solidified analyst conviction in Soleno's market position, with H.C. Wainwright, Baird, and TD Cowen all reiterating positive ratings with price targets of $110, $121, and $120, respectively. While Stifel slightly moderated its price target to $115 from $118, it maintained a Buy rating, basing its adjustment on a refreshed market model projecting 50% penetration of the target population. This model still supports a substantial worldwide market opportunity valued at over $2 billion. The company's fundamental momentum is further evidenced by the successful, expectation-beating launch of Vykat XR and positive feedback on the drug's safety profile. While analysts caution that a Q2 'bolus' effect may temper linear growth extrapolation, the potential for European Union expansion next year presents a meaningful future catalyst.

Key Decisions for Investors

• Investors should view the failure of Acadia's competing drug as a significant positive catalyst for Soleno, as it clears the competitive landscape and strengthens the commercial pathway for its Vykat treatment in the PWS market.
• Despite the stock's 50.39% year-to-date appreciation, the cluster of analyst price targets ranging from $110 to $121 suggests a consensus view of significant remaining upside from the current price of $67.60.
• Monitor the commercial execution of Vykat XR and any announcements regarding European expansion, as these are the next key catalysts, while being mindful that sequential growth may moderate following a one-time 'bolus' effect in recent results.
• For those holding Acadia Pharmaceuticals, its PWS trial failure represents a material setback that warrants a re-evaluation of that specific pipeline asset's contribution to the company's valuation.